insights_auto
Outlook: 63.3% bullish·3.3% bearish
Go to analysischevron_right
INO:NASDAQ
Inovio Pharmaceuticals Inc
US$1.44
arrow_downward
-1.37%(-0.020) 1D
ኖቬም 13, 12:56:46 ከሰዓት ጂ ኤም ቲ-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INO...
Open
US$1.44
High
US$1.48
Low
US$1.39
Mkt. cap
269.72 ሚ
Avg. vol.
19.26 ሚ
Volume
3.07 ሚ
52-wk high
US$2.72
52-wk low
US$0.57
EPS
-US$0.80
Beta
1.71
Shares outstanding
187.31 ሚ
No. of employees
112
Open
US$1.44
High
US$1.48
Low
US$1.39
Mkt. cap
269.72 ሚ
Avg. vol.
19.26 ሚ
Volume
3.07 ሚ
52-wk high
US$2.72
52-wk low
US$0.57
EPS
-US$0.80
Beta
1.71
Shares outstanding
187.31 ሚ
No. of employees
112
News stories
From web sources and news partners
Seeking Alpha
·
ከ28 ደቂቃዎች በፊት
Inovio Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:INO) 2026-11-13
News Corp
·
ከ19 ሰዓቶች በፊት
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
MarketWatch
·
ከ19 ሰዓቶች በፊት
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
GuruFocus
·
ከ1 ቀን በፊት
Inovio Pharmaceuticals Inc (INO) (Q3 2026) Earnings Call Highlig
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteinovio.com